Areas of Research: I lead the Einstein-Montefiore Institute for Clinical and Translational Research (CTSA). My research programs in the past focused type 1 and type 2 diabetes, funded via mechanistic physiology grants and NIH clinical trials.
Dr. Shamoon is Associate Dean for Clinical & Translational Research, Director of the Harold and Muriel Block Institute for Clinical & Translational Research at Einstein and Montefiore (ICTR), and Professor of Medicine (Endocrinology, Diabetes and Metabolism).
The Block ICTR houses the Clinical and Translational Science Award (CTSA) program funded by the NIH. The CTSA consortium, a group of the 62 leading US medical research institutions works together to improve the way biomedical research is conducted, and shares a common vision of accelerating laboratory discoveries and engaging communities in clinical research to bring discoveries and prevention into parctice. It is also focusing on the training the next generation of clinical investigators. The Block ICTR represents the research partnership between Albert Einstein College of Medicine and Montefiore Health System which strives to support the CTSA vision.
Over the past 35 years, Dr. Shamoon's laboratory studied the mechanisms and treatment for defective counterregulation of hypoglycemia in type 1 diabetes. He and colleagues established the fundamental link between reduced epinephrine and glucagon secretion and impaired hepatic glucose production in response to hypoglycemia. Further studies elucidated the stimulus-specificity of the responses to hypoglycemia and the resultant defects in glucose counterregulation, the existence of hepatic "autoregulation" by glucose per se, and the role of glucokinase activation in restoring impaired counterregulation in diabetes. His group has also established the contributions of hepatic glycogen metabolism and gluconeogenesis to glucose counterregulation in humans using in vivo MR spectroscopy. In addition, Dr. Shamoon directed the major diabetes clinical trials at Einstein, including the Diabetes Control and Complications Trial, the landmark study that established the benefits of intensive glycemic control in type 1 diabetes, and the Diabetes Prevention Program in type 2 diabetes. Dr. Shamoon has been elected to the American Society of Clinical Investigation (1992), the American Association of Physicians (1998), and the New York Academy of Medicine (2003).
More Information About Dr. Harry Shamoon
Harold and Muriel Block Institute for Clinical and Translational Research at Einstein and Montefiore
Diabetes Research Center
Material in this section is provided by individual faculty members who are solely responsible for its accuracy and content.